Key facts
- Thermo Fisher reported Q2 adjusted EPS of $6.03 on $11.99 billion in sales, exceeding analyst expectations.
- The company raised its 2026 adjusted EPS outlook to $24.93-$25.33, signaling confidence in future profitability.
- Demand recovery was observed across all of Thermo Fisher's business segments.
- The Analytical Instruments division showed particularly strong performance with a 30.5% surge in segment income.
- Thermo Fisher's positive results suggest a broader recovery in spending by biotech and pharmaceutical customers.
Thermo Fisher Scientific's stock rose approximately 10% after the company reported second-quarter results that exceeded Wall Street's expectations and raised its 2026 profit outlook. The life sciences tools provider announced adjusted earnings per share of $6.03 on $11.99 billion in sales, surpassing consensus estimates of $5.71 per share and $11.70 billion in sales.
Management attributed the strong performance to a recovery in demand across its various markets, with results improving in every segment. The Analytical Instruments division was a particular highlight, showing a 6.9% increase in revenue and a significant 30.5% surge in segment income, contributing substantially to overall profit growth. This segment's profit increased at a higher rate than its sales, widening its margin by 420 basis points to 23.0%.
The company updated its 2026 adjusted earnings per share forecast to a range of $24.93 to $25.33, up from the previous guidance of $24.64 to $25.12. This upward revision is seen as an indicator that customers in the biotech and pharmaceutical sectors are resuming research and manufacturing activities after a post-pandemic slowdown. However, the recovery is described as uneven, with muted demand noted in China and a cautious funding environment in the U.S. for academic and government clients.
Thermo Fisher maintained its 2026 revenue forecast between $47.4 billion and $48.1 billion. The company's performance also provides a positive read-through for the broader life sciences tools sector. Analysts at Evercore ISI suggested that a recent order postponement by peer Danaher Corp. was company-specific, and that Thermo Fisher's results support the notion of a genuine industry-wide turnaround. Danaher's shares also advanced following its own earnings report.